KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Teva Pharmaceutical Industries (TEVA) Invested Capital (2016 - 2026)

Teva Pharmaceutical Industries filings provide 18 years of Invested Capital readings, the most recent being $10.8 billion for Q1 2026.

  • On a quarterly basis, Invested Capital rose 62.03% to $10.8 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $10.8 billion, a 62.03% increase, with the full-year FY2025 number at $9.7 billion, up 35.93% from a year prior.
  • Invested Capital hit $10.8 billion in Q1 2026 for Teva Pharmaceutical Industries, up from $9.7 billion in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $12.3 billion in Q1 2022 to a low of $6.7 billion in Q1 2025.
  • Median Invested Capital over the past 5 years was $9.6 billion (2023), compared with a mean of $9.5 billion.
  • Biggest five-year swings in Invested Capital: plummeted 36.9% in 2025 and later soared 62.03% in 2026.
  • Teva Pharmaceutical Industries' Invested Capital stood at $10.7 billion in 2022, then dropped by 8.49% to $9.8 billion in 2023, then dropped by 26.91% to $7.2 billion in 2024, then skyrocketed by 35.93% to $9.7 billion in 2025, then rose by 11.36% to $10.8 billion in 2026.
  • The last three reported values for Invested Capital were $10.8 billion (Q1 2026), $9.7 billion (Q4 2025), and $7.3 billion (Q3 2025) per Business Quant data.